MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$65.97M, compared with -$40.01M a year earlier. Trailing-twelve-month EBITDA was -$245.81M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -83.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$65.97M-9.9% QoQ
- Last fiscal yearDec 2025
- -$219.85M-83.9% YoY
- LTMMar 2026
- -$245.81M-69.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -64.9% | +100.0% | +164.9 pp |
| 1 year | -83.9% | +100.0% | +183.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (219.85M) USD
- Year-over-year change
- -83.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (219.85M) | -83.9% |
| FY2024 | 2024-12-31 | (119.58M) | -174.2% |
| FY2023 | 2023-12-31 | (43.61M) | +32.2% |
| FY2022 | 2022-12-31 | (64.3M) | -19.9% |
| FY2021 | 2021-12-31 | (53.63M) | — |
EBITDA vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 EBITDA of -$245.81M is the 10th highest of the 11 companies compared; the peer median is -$60.47M.
- Its year-over-year change of -69.1% is the 10th highest of 11, against a peer median of -26.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Mar 2026 | $58.49M | +176.6% | — | 25.2% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Jun 2026 | -$29.53M | +74.2% | — | 1550.9% | |
| FY2025 | -$54.58M | -270.2% | — | 85279.7% | |
| FY2025 | -$66.36M | -60.9% | — | 4915.2% | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$161.31M | -42.5% | — | — |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| Peer median (excluding MLTX) | -$60.47M | -26.5% | — | 1550.9% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.97K | 0 | 0 | 0 | 2.62M |
| Gross Profit | (4.97K) | 0 | 0 | 0 | (2.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.52M | 42.05M | 31.8M | 112.77M | 202.86M |
| Selling, General & Admin | 18.05M | 23.01M | 22.32M | 30.32M | 41.97M |
| Operating Expenses | 53.57M | 65.06M | 54.12M | 143.09M | 242.22M |
| Depreciation & Amortization | 4.97K | 164.78K | 370.32K | 1.38M | 2.62M |
| EBITDA | (53.63M) | (64.3M) | (43.61M) | (119.58M) | (219.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (53.58M) | (65.06M) | (54.12M) | (143.09M) | (244.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 7.25M |
| Other Income / Expenses | (61.85K) | 591.73K | 10.14M | 22.13M | 15.12M |
| Income Before Tax | (53.64M) | (64.47M) | (43.98M) | (120.96M) | (229.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 4.76K | 36.37K | 94.39K | 282.2K | 611K |
| Net Income | (53.64M) | (49.97M) | (36.01M) | (118.94M) | (227.32M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| EPS (Diluted) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| Weighted Avg Shares | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
| Weighted Avg Shares (Diluted) | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.